Elom Hilary A, Hegazy Yassmin, Lerma Edgar V, Hassanein Mohamed
Department of Medicine, University of Missouri School of Medicine, United States.
Department of Medicine, Columbia University, United States.
Indian J Nephrol. 2025 Jan-Feb;35(1):21-28. doi: 10.25259/ijn_333_23. Epub 2024 Jun 24.
Acute kidney injury (AKI) is a frequent complication of chronic liver disease (CLD) contributing to high morbidity and mortality worldwide. While liver transplantation (LT) has shown favorable outcomes, early identification and management of AKI is imperative for survival. This review aims to highlight the epidemiology, pathophysiology, management, and prognosis of AKI in CLD.
An extensive literature search was performed using PubMed, Medline, and Google Scholar to identify literature related to epidemiology, burden, clinical presentations, prognosis, and management of AKI in CLD.
The identified studies highlighted a wide range of prevalence of AKI in hospitalized patients with CLD. The etiology and pathophysiology are multifactorial and include prerenal AKI, acute tubular injury, sepsis, gastrointestinal bleeding, bacterial translocation from the gut, and hepatorenal syndrome (HRS). AKI is associated with a higher risk of morbidity and mortality and progression to chronic kidney disease following LT. Management of AKI in CLD varies based on the underlying etiology. While vasoconstrictors like terlipressin have shown great potential in the treatment of HRS-AKI and is widely used in Europe and United States, LT remains the definitive therapy of choice. In most cases, kidney replacement therapy serves as a bridge to liver transplant.
AKI is a serious complication of CLD and early identification is essential. Diagnosis and management, particularly HRS is challenging and requires a high index of suspicion. More research is required to identify novel therapies to improve outcomes of AKI in patients with CLD.
急性肾损伤(AKI)是慢性肝病(CLD)常见的并发症,在全球范围内导致高发病率和死亡率。虽然肝移植(LT)已显示出良好的疗效,但对AKI进行早期识别和管理对于患者生存至关重要。本综述旨在强调CLD中AKI的流行病学、病理生理学、管理和预后。
使用PubMed、Medline和谷歌学术进行广泛的文献检索,以识别与CLD中AKI的流行病学、负担、临床表现、预后和管理相关的文献。
已识别的研究突出了CLD住院患者中AKI的广泛患病率。病因和病理生理学是多因素的,包括肾前性AKI、急性肾小管损伤、脓毒症、胃肠道出血、肠道细菌移位和肝肾综合征(HRS)。AKI与更高的发病率和死亡率风险以及LT后进展为慢性肾脏病相关。CLD中AKI的管理因潜在病因而异。虽然特利加压素等血管收缩剂在治疗HRS-AKI方面显示出巨大潜力,并在欧洲和美国广泛使用,但LT仍然是最终的治疗选择。在大多数情况下,肾脏替代疗法是肝移植的桥梁。
AKI是CLD的严重并发症,早期识别至关重要。诊断和管理,尤其是HRS具有挑战性,需要高度的怀疑指数。需要更多研究来确定新的疗法,以改善CLD患者AKI的预后。